Page 1

ZEISS Quarterly Statement 3 Months 2020/21 Quarterly Statement of the Carl Zeiss Meditec Group - 3 months FY2020 / 21 - ■ - ■ Revenue stable overall compared with prior year , in spite of effects of COVID - 19 pandemic Return to growth in APAC¹ region – Revenue in EMEA² and Americas around previous year's level after adjustment for currency effects Operating result of € 73.4m and EBIT margin increases to 19.9 % Management expects recovery of revenue and earnings to continue compared with previous fiscal year , which was dominated by COVID - 19 pandemic Business development within the Group • The Carl Zeiss Meditec Group generated revenue of € 368.9m in the first three months of fiscal year 2020/21 , coming close to matching the year - ago figure of € 369.7m ( -0.2 % ) . Currency effects had a material adverse effect , however ; currency - adjusted growth amounted to + 2.6 % . While the Ophthalmic Devices strategic business unit reported a positive revenue trend , bolstered by the strong recurring revenue , revenue in the Microsurgery strategic business unit was still on a decline due in particular to ongoing restrictions in relation to the COVID - 19 pandemic . The APAC region was already recording good growth again in the first quarter of fiscal year 2020/21 . The revenue trend in the EMEA region was also largely stable compared with the prior year , while the Americas region showed a decline in revenue after adjustment for currency effects . 1 Asia / Pacific 2 Europe / Middle East / Africa Page 1